Baseimmune Raises $11.3M in Series A funding to Develop Better Vaccines Faster
View the full release here: https://www.businesswire.com/news/home/20240219023333/en/
- View the full release here: https://www.businesswire.com/news/home/20240219023333/en/
From left to right: Baseimmune co-founders Ariane C. Gomes (Chief Scientific Officer), Phillip Kemlo (Chief Technology Officer), and Joshua Blight (Chief Executive Officer). - Photo credit: Baseimmune
“We’re thrilled to have the support of a top-tier investor syndicate led by MSD Global Health Innovation Fund and IQ Capital. - This funding will enable us to accelerate the development of our technology, scale our programs, and expedite the delivery of impactful vaccines against future pathogens,” said Joshua Blight, CEO & Co-Founder, Baseimmune.
- By using big data and a design algorithm, Baseimmune has been able to shorten the time it takes to develop a vaccine candidate.